128 related articles for article (PubMed ID: 27774524)
1. Granzyme B Contributes to the Optimal Graft-Versus-Tumor Effect Mediated by Conventional CD4
Du W; Leigh ND; Bian G; Alqassim E; O'Neill RE; Mei L; Qiu J; Liu H; McCarthy PL; Cao X
J Immunol Res Ther; 2016; 1(1):22-28. PubMed ID: 27774524
[TBL] [Abstract][Full Text] [Related]
2. Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect.
Du W; Mohammadpour H; O'Neill RE; Kumar S; Chen C; Qiu M; Mei L; Qiu J; McCarthy PL; Lee KP; Cao X
Oncoimmunology; 2018; 7(3):e1397247. PubMed ID: 29399396
[TBL] [Abstract][Full Text] [Related]
3. Granzyme B-mediated damage of CD8+ T cells impairs graft-versus-tumor effect.
Bian G; Ding X; Leigh ND; Tang Y; Capitano ML; Qiu J; McCarthy PL; Liu H; Cao X
J Immunol; 2013 Feb; 190(3):1341-50. PubMed ID: 23264653
[TBL] [Abstract][Full Text] [Related]
4. Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease.
Du W; Leigh ND; Bian G; O'Neill RE; Mei L; Qiu J; Chen GL; Hahn T; Liu H; McCarthy PL; Cao X
J Immunol; 2015 Nov; 195(9):4514-23. PubMed ID: 26392464
[TBL] [Abstract][Full Text] [Related]
5. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Host-Derived Serine Protease Inhibitor 6 Provides Granzyme B-Independent Protection of Intestinal Epithelial Cells in Murine Graft-versus-Host Disease.
Mohammadpour H; Du W; O'Neill R; Khalili S; Qiu J; Repasky EA; McCarthy PL; Cao X
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2397-2408. PubMed ID: 30006303
[TBL] [Abstract][Full Text] [Related]
8. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
9. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
[TBL] [Abstract][Full Text] [Related]
10. Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease.
Soares MV; Azevedo RI; Ferreira IA; Bucar S; Ribeiro AC; Vieira A; Pereira PNG; Ribeiro RM; Ligeiro D; Alho AC; Soares AS; Camacho N; Martins C; Lourenço F; Moreno R; Ritz J; Lacerda JF
Front Immunol; 2019; 10():334. PubMed ID: 30894856
[TBL] [Abstract][Full Text] [Related]
11. A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD management.
Avivi I; Stroopinsky D; Rowe JM; Katz T
Transpl Immunol; 2013 Jan; 28(1):57-61. PubMed ID: 23196257
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.
Toubai T; Tamaki H; Peltier DC; Rossi C; Oravecz-Wilson K; Liu C; Zajac C; Wu J; Sun Y; Fujiwara H; Henig I; Kim S; Lombard DB; Reddy P
J Immunol; 2018 Dec; 201(11):3443-3455. PubMed ID: 30389773
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
Du W; Cao X
Front Immunol; 2018; 9():2979. PubMed ID: 30631325
[TBL] [Abstract][Full Text] [Related]
14. T cells require TRAIL for optimal graft-versus-tumor activity.
Schmaltz C; Alpdogan O; Kappel BJ; Muriglan SJ; Rotolo JA; Ongchin J; Willis LM; Greenberg AS; Eng JM; Crawford JM; Murphy GF; Yagita H; Walczak H; Peschon JJ; van den Brink MR
Nat Med; 2002 Dec; 8(12):1433-7. PubMed ID: 12426560
[TBL] [Abstract][Full Text] [Related]
15. MyD88 Costimulation in Donor CD8
Ciavattone NG; Wu L; O'Neill R; Qiu J; Davila E; Cao X
J Immunol; 2021 Feb; 206(4):892-903. PubMed ID: 33408257
[TBL] [Abstract][Full Text] [Related]
16. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
17. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
18. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
[TBL] [Abstract][Full Text] [Related]
19. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.
Ramirez-Montagut T; Chow A; Kochman AA; Smith OM; Suh D; Sindhi H; Lu S; Borsotti C; Grubin J; Patel N; Terwey TH; Kim TD; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
J Immunol; 2007 Aug; 179(3):1669-80. PubMed ID: 17641033
[TBL] [Abstract][Full Text] [Related]
20. Solid Tumor-Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogenic Bone Marrow Transplantation.
Dang N; Lin Y; Rutgeerts O; Sagaert X; Billiau AD; Waer M; Sprangers B
Cancer Res; 2019 May; 79(10):2709-2721. PubMed ID: 30936086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
